Neurocrine Biosciences | NBIX - Net Income


Neurocrine Biosciences reported $209.5M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Acadia Pharmaceuticals USD 273.57M 201.79M Dec/2025
Agios Pharmaceuticals USD -108.04M 4.61M Dec/2025
ALKERMES USD 49.34M 33.42M Dec/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
Amgen USD 1.33B 1.88B Dec/2025
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Cytokinetics USD -183.03M 123.15M Dec/2025
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
Exelixis USD 193.58M 8.73M Sep/2025
Gilead Sciences USD 2.18B 869M Dec/2025
Halozyme Therapeutics USD -141.59M 316.82M Dec/2025
Incyte USD 299.28M 124.89M Dec/2025
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
Nektar Therapeutics USD -37.06M 15.31M Sep/2024
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
Prothena USD -36.54M 89.23M Sep/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Repligen USD 13.29M 1.62M Dec/2025
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
Sarepta Therapeutics USD -412.23M 232.28M Dec/2025
Teva Pharmaceutical Industries USD 480M 47M Dec/2025
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
Vertex Pharmaceuticals USD 1.19B 108.2M Dec/2025
Xoma USD -17.24M 33.23M Sep/2024